Overview

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

Status:
Withdrawn
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia
Phase:
N/A
Details
Lead Sponsor:
L.V. Prasad Eye Institute
Collaborator:
Pfizer